These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis. Thiele S; Mungalpara J; Steen A; Rosenkilde MM; Våbenø J Br J Pharmacol; 2014 Dec; 171(23):5313-29. PubMed ID: 25039237 [TBL] [Abstract][Full Text] [Related]
8. G protein‑mediated EGFR transactivation is a common mechanism through which the CXCL12 receptors, CXCR4 and CXCR7, control human cancer cell migration. Zieger-Naumann K; Kuhl F; Engele J Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38099418 [TBL] [Abstract][Full Text] [Related]
9. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. Heinrich EL; Lee W; Lu J; Lowy AM; Kim J J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349 [TBL] [Abstract][Full Text] [Related]
10. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Luker KE; Steele JM; Mihalko LA; Ray P; Luker GD Oncogene; 2010 Aug; 29(32):4599-610. PubMed ID: 20531309 [TBL] [Abstract][Full Text] [Related]
11. CXCR7 controls competition for recruitment of β-arrestin 2 in cells expressing both CXCR4 and CXCR7. Coggins NL; Trakimas D; Chang SL; Ehrlich A; Ray P; Luker KE; Linderman JJ; Luker GD PLoS One; 2014; 9(6):e98328. PubMed ID: 24896823 [TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship study of a CXC chemokine receptor type 4 antagonist, FC131, using a series of alkene dipeptide isosteres. Kobayashi K; Oishi S; Hayashi R; Tomita K; Kubo T; Tanahara N; Ohno H; Yoshikawa Y; Furuya T; Hoshino M; Fujii N J Med Chem; 2012 Mar; 55(6):2746-57. PubMed ID: 22352868 [TBL] [Abstract][Full Text] [Related]
13. The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells. Odemis V; Lipfert J; Kraft R; Hajek P; Abraham G; Hattermann K; Mentlein R; Engele J Glia; 2012 Mar; 60(3):372-81. PubMed ID: 22083878 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of scaffold-based tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4). Zachariassen ZG; Thiele S; Berg EA; Rasmussen P; Fossen T; Rosenkilde MM; Våbenø J; Haug BE Bioorg Med Chem; 2014 Sep; 22(17):4759-69. PubMed ID: 25082513 [TBL] [Abstract][Full Text] [Related]
16. Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12. Benredjem B; Girard M; Rhainds D; St-Onge G; Heveker N J Biol Chem; 2017 Jan; 292(1):31-42. PubMed ID: 27875312 [TBL] [Abstract][Full Text] [Related]
17. Expression and function of the SDF-1 chemokine receptors CXCR4 and CXCR7 during mouse limb muscle development and regeneration. Hunger C; Ödemis V; Engele J Exp Cell Res; 2012 Oct; 318(17):2178-90. PubMed ID: 22766125 [TBL] [Abstract][Full Text] [Related]
18. The chemokine X-factor: Structure-function analysis of the CXC motif at CXCR4 and ACKR3. Wedemeyer MJ; Mahn SA; Getschman AE; Crawford KS; Peterson FC; Marchese A; McCorvy JD; Volkman BF J Biol Chem; 2020 Oct; 295(40):13927-13939. PubMed ID: 32788219 [TBL] [Abstract][Full Text] [Related]
19. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach. Costantini S; Raucci R; De Vero T; Castello G; Colonna G Cytokine; 2013 Oct; 64(1):316-21. PubMed ID: 23773308 [TBL] [Abstract][Full Text] [Related]